Total Payments
$425,777
2024 Payments
$35,483
Companies
6
Transactions
136
Payment Breakdown by Category
Research$407,904 (95.8%)
Travel$16,655 (3.9%)
Food & Beverage$1,217 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $407,904 | 56 | 95.8% |
| Travel and Lodging | $16,655 | 53 | 3.9% |
| Food and Beverage | $1,217 | 27 | 0.3% |
Payments by Type
Research
$407,904
56 transactions
General
$17,873
80 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $281,105 | 25 | $0 (2017) |
| Eli Lilly and Company | $140,367 | 76 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $2,125 | 15 | $0 (2019) |
| GlaxoSmithKline, LLC. | $1,334 | 6 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $782.12 | 10 | $0 (2024) |
| AbbVie Inc. | $63.37 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,483 | 16 | Eli Lilly and Company ($34,701) |
| 2023 | $14,155 | 54 | Eli Lilly and Company ($14,092) |
| 2022 | $13,513 | 16 | Eli Lilly and Company ($13,513) |
| 2020 | $78,061 | 4 | Eli Lilly and Company ($78,061) |
| 2019 | $2,125 | 15 | Regeneron Pharmaceuticals, Inc. ($2,125) |
| 2017 | $282,439 | 31 | Rhodes Pharmaceuticals L.P. ($281,105) |
All Payment Transactions
136 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $261.06 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $261.06 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.00 | General |
| 10/01/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $206.41 | General |
| 10/01/2024 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $70.59 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,823.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,673.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,255.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 05/13/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,672.87 | Research |
| 11/02/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: NEUROSCIENCE | ||||||
| 09/07/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: NEUROSCIENCE | ||||||
| 08/03/2023 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $147.72 | General |
| 08/03/2023 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $89.24 | General |
| 06/12/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: NEUROSCIENCE | ||||||
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $2,246.47 | General |
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1,939.95 | General |
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1,926.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RP-BP-EF003 | Rhodes Pharmaceuticals L.P. | $210,182 | 14 |
| RP-BP-EF004 | Rhodes Pharmaceuticals L.P. | $70,923 | 11 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $61,287 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $15,823 | 1 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $13,368 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $10,261 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $4,000 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $3,673 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $2,255 | 1 |
| A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $2,125 | 15 |
| A randomised, double blind, parallel group, multicentre, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate vilanterol inhalation powder compared to once daily fluticasone furoate inhalation powder in the treatment of a | GlaxoSmithKline, LLC. | $1,334 | 6 |
About Dr. J Sartore, MD
Dr. J Sartore, MD is a Family Medicine healthcare provider based in Evansville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356419840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. J Sartore, MD has received a total of $425,777 in payments from pharmaceutical and medical device companies, with $35,483 received in 2024. These payments were reported across 136 transactions from 6 companies. The most common payment nature is "" ($407,904).
Ad
Practice Information
- Specialty Family Medicine
- Location Evansville, IN
- Active Since 12/01/2006
- Last Updated 12/31/2008
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1356419840
Products in Payments
- Aptensio XR (Drug) $281,105
- VRAYLAR (Drug) $63.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Evansville
David Schultz, M.d, M.D
Family Medicine — Payments: $756,324
Family Medicine $756,324
Dr. Anthony Inzerello, M.d, M.D
Family Medicine — Payments: $315,157
Family Medicine $315,157
Carol Goodman, Md, MD
Family Medicine — Payments: $125,655
Family Medicine $125,655
Randall Oliver, M.d, M.D
Family Medicine — Payments: $75,540
Family Medicine $75,540
David Brougher, M.d, M.D
Family Medicine — Payments: $62,934
Family Medicine $62,934
Dr. Eric Jackson, M.d, M.D
Family Medicine — Payments: $46,422
Family Medicine $46,422